Tran Capital Management L.P. Sells 10,761 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Tran Capital Management L.P. cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,113 shares of the medical research company’s stock after selling 10,761 shares during the period. IQVIA comprises approximately 2.8% of Tran Capital Management L.P.’s investment portfolio, making the stock its 16th largest holding. Tran Capital Management L.P. owned 0.07% of IQVIA worth $24,586,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the 3rd quarter worth about $27,000. Park Place Capital Corp purchased a new position in IQVIA in the third quarter valued at about $28,000. Avior Wealth Management LLC increased its stake in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. lifted its stake in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 99 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on IQV shares. Morgan Stanley dropped their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. TD Cowen dropped their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Truist Financial reduced their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Bank of America dropped their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Trading Down 0.7 %

Shares of IQV opened at $204.54 on Friday. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a market capitalization of $37.12 billion, a P/E ratio of 26.84, a P/E/G ratio of 2.14 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm’s 50 day simple moving average is $199.71 and its 200 day simple moving average is $221.06.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.